Synapes Life Sciences

Development and provision of pharmaceutical medicines in healthcare sectors, focusing on critical care and patient outcomes.
Request Access
Report Incorrect Data
Annual revenue $425,249 Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products 2 Services tracked
Competitors - Brand Intelligence

About Synapes Life Sciences

Synapes Life Sciences is a company. Synapes Life Sciences offers products and services including LEVODRIFT Inj. and MAROGOLD 250 Inj..

Operational Areas
Healthcare → Healthcare Products & Supplies → Unlock Sub-Sector → Unlock Segment
Healthcare → Health Technology & Digital Health → Unlock Sub-Sector → Unlock Segment
Key Metrics
  • Annual Revenue
    $425.25 K (USD)
    60.52
    as on Mar 31, 2022
  • Net Profit
    $12 K (USD)
    57.01
    as on Mar 31, 2022
  • EBITDA
    $24.47 K (USD)
    90.03
    as on Mar 31, 2022
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Synapes Life Sciences

Synapes Life Sciences offers a comprehensive portfolio of products and services, including LEVODRIFT Inj. and MAROGOLD 250 Inj..

Product name locked
Category locked
Primary

This injection, containing Levosulpiride, is utilized for medical treatments in relevant healthcare segments.

Product name locked
Category locked
Locked

This injection, featuring Meropenum, is employed for therapeutic purposes in critical care applications.

Funding Insights of Synapes Life Sciences

Premium access

Detailed funding history for Synapes Life Sciences

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Synapes Life Sciences

Investments
Premium access

Investment portfolio details for Synapes Life Sciences

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Synapes Life Sciences

Premium access

Detailed financials for Synapes Life Sciences

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Synapes Life Sciences Comparisons

Synapes Life Sciences Primary company
Description
Development and provision of pharmaceutical medicines in hea...
Location
-
Founded Year
-
Annual Revenue
$425.25 K (USD)
Net Profit
$12 K (USD)
EBITDA
$24.47 K (USD)
Employees
Not available
Premium access

Peer comparison for Synapes Life Sciences

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Synapes Life Sciences

Premium access

Detailed competitors of Synapes Life Sciences

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Synapes Life Sciences

Premium access

Complete news archive for Synapes Life Sciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Synapes Life Sciences

Annual revenue of Synapes Life Sciences is $425.25K as on Mar 31, 2022.

Synapes Life Sciences is noted for developing medicines that enhance patient outcomes in critical care, neurology, and nephrology, with a 25-year history of operations covering major hospitals. Collaborations with healthcare providers and technology firms are utilized to improve product benefits and access to care. Integrity and transparency are emphasized in business practices, including ethical policies in finance, human resources, sales, and production. The organization is recognized for its commitment to expanding healthcare access and maintaining high standards, as demonstrated through its services and technologies.

Synapes Life Sciences offers LEVODRIFT Inj. and MAROGOLD 250 Inj..

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available